化合物NEO2734 T8658

Product Introduction
Bioactivity


英文名: NEO2734

描述: NEO2734 (EP31670) 是一种具有口服活性的选择性 p300/CBP 和 BET 溴结构域抑制剂，其 IC50值均小于30 nM，可用于前列腺癌的研究。

体外活性: NEO2734, a novel dual inhibitor of BET and CBP/p300, is active in both hotspot mutant (F133V) and non-hotspot mutant (Q165P) PCa cells in vitro and in vivo[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 27.5 mg/mL (63.15 mM)


关键字: NEO-2734 | PER-403 | SPOP | CBP | MYC | HAT | Epigenetic Reader Domain | NEO 2734 | TC-797 | Histone Acetyltransferase | p300 | HATs | inhibit | Inhibitor | EP 31670 | EP-31670 | NEO2734

相关产品: PROTAC BET Degrader-1 | HJB97 | UNC1215 | CBP/p300-IN-21 | BD-9136 | SNDX-5613 | PROTAC BRD3/BRD4-L degrader-2 | ZEN-3862 | M‑89 | MG 149

相关库: Anti-Prostate Cancer Compound Library | Anti-Hypertension Compound Library | Anti-Cancer Compound Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Active Compound Library | Target-Focused Phenotypic Screening Library | Preclinical Compound Library | Covalent Inhibitor Library

化合物NEO2734 T8658信息由TargetMol中国为您提供，如您想了解更多关于化合物NEO2734 T8658报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途